Clinical effects of cervical local implantation chemotherapy combined with synchronal radiochemotherapy in advanced cervical cancer
10.3760/cma.j.issn.1008-6315.2011.05.030
- VernacularTitle:宫颈植入性化疗协同同步放化疗治疗中晚期子宫颈癌临床疗效分析
- Author:
Lei WAN
;
Longyu LI
;
Siyuan ZENG
;
Shaoyong WU
;
Yunyan WU
;
Yi WANG
- Publication Type:Journal Article
- Keywords:
Local implantation chemotherapy;
Synchronal radiochemotherapy;
Cervical cancer
- From:
Clinical Medicine of China
2011;27(5):530-532
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical effects and side events between simple synchronal radiochemotherapy(group A) and cervical local implantation chemotherapy combined with synchronal radiochemotherapy(group B) in advanced cervical cancer.Methods Sixty patients with primary cervical cancer,admitted to our hospital from January 2009 to December 2009,were enrolled into the study.The clinical staging of these patients ranged from Ⅱb to Ⅲb.The patients were randomly divided into two different therapy groups.In group A,patients received external irradiation by X-rays and intracavitary by 192 Ir and PT chemotherapy(n=30).In group B,patients received cervical local implantation of fluorouracil palliative 400-500 mg in addition of external irradiation by X-rays and intracavitary by 192 Ir and PT chemotherapy(n=30).The short-term effect and complications were compared between the two groups.Results The effective rate of group A was significantly higher than the second group(97% vs.80%,x2=4.706,P＜ 0.05).The most common complication was myelosuppression.In group A we observed 8 cases had grade Ⅰ,10 cases had grade II,9 cases had grade Ⅲ,3 cases had grade Ⅳ myelosuppression.In group B we observed 8 cases had grade Ⅰ,12 cases had grade Ⅱ,7 cases had grade Ⅲ,3 cases had grade Ⅳ myelosuppression.There were no significantly differences in the comparisons of this complication between the two groups(x2=0.432,P＞0.05).Conclusion The cervical local implantation chemotherapy combined with synchronal radiochemotherapy might improve the prognosis in advanced cervical cancer patients without increasing toxic side effects.
